James Timothy Aluri, MD

Dr. Seyed Ali Mosallaie is an assistant professor in the Division of Nuclear Medicine, with a clinical and research focus on radiotheranostics. He obtained his medical degree from Tehran Islamic Azad University — Faculty of Medicine in Iran. Dr. Mosallaie joined the biomedical engineering faculty and served as the medical director of the University Health Center at Islamic Azad University, Qazvin. Dr. Mosallaie completed radiology residency training at Cebu Doctors University Hospital in the Philippines. He also completed nuclear medicine residency training at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a course in research and clinical fellowship training in neuroradiology at Thomas Jefferson University Hospital in Philadelphia. He then pursued PET/CT fellowship training at The Johns Hopkins Hospital.

Dr. Ashish Doshi is a pediatric cardiologist specializing in advanced cardiac imaging at Johns Hopkins Children’s Center in Baltimore, Maryland.Dr. Doshi completed a combined M.D./Ph.D. program at Duke University School of Medicine. His doctoral research was in the field of biomedical engineering, specifically computational modeling of cardiac electrophysiology. He completed his pediatrics residency at St. Louis Children’s Hospital, followed by a fellowship in pediatric cardiology at Children’s National Hospital in Washington, DC. During his cardiology fellowship, Dr. Doshi conducted research at The Johns Hopkins University School of Engineering. After finishing fellowship, he continued this work through a research fellowship funded by the American Heart Association, investigating MRI-based computational models for arrhythmia risk prediction in tetralogy of Fallot and pediatric myocarditis. He subsequently completed training in advanced cardiac imaging at Johns Hopkins Children’s Center.Dr. Doshi’s research interests involve the use of computational methods, particularly image-based biomedical modeling and computer simulation, for risk stratification and clinical decision support in children with congenital and acquired heart disease, with particular interests in hypertrophic cardiomyopathy, repaired tetralogy of Fallot, and single-ventricle disease. He has also conducted work in fetal electrocardiography and the use of cardiac MRI native T1 mapping for detection of heart transplant rejection.

Matthew Robinson, MD, is Assistant Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. He is interested in leveraging diagnostic innovation and precision medicine to reduce diagnostic and prognostic uncertainty for infectious diseases. His current projects include applications in global health, antimicrobial resistance, antibiotic stewardship, infection control, COVID-19, acute febrile illness, and tuberculosis.After undergraduate and medical school at Northwestern University, he completed internal medicine residency at New York University and Infectious Diseases fellowship at Johns Hopkins School of Medicine. During medical school, he worked at the Chinese Center for Disease Control and Prevention in Beijing, China under a Doris Duke International Clinical Research Fellowship. He also served as a clinician educator in internal medicine in Gulu, Uganda at the Gulu University Faculty of Medicine as a Global Health Service Partnership volunteer. As a fellow, he pursued a Fogarty Global Health Fellowship in Pune, India and an Antibacterial Resistance Leadership Group Fellowship.Since joining the faculty in 2019, Dr. Robinson has been supported by the Centers for Disease Control and Prevention, National Institutes of Health, and Food and Drug Administration. The focus of his work in antimicrobial resistance, antibiotic stewardship, infection control has been to characterize drug-resistant Gram-negative infections in India. His work with the Johns Hopkins Precision Medicine Center of Excellence for COVID-19 has included applying machine learning and causal inference techniques to predict COVID-19 outcomes. He has contributed to SARS-CoV-2 diagnostic development through the NIH Rapid Acceleration of Diagnostics (RADx) initiative and through collaborative development of other novel diagnostics.